干细胞
造血
离体
移植
血小板生成素
异种移植
生物
细胞生物学
免疫学
干细胞因子
癌症研究
体内
医学
内科学
生物技术
作者
Masatoshi Sakurai,Kantaro Ishitsuka,Ryoji Ito,Adam C. Wilkinson,Takaharu Kimura,Eiji Mizutani,Hidekazu Nishikii,Kazuhiro Sudo,H. Becker,Hiroshi Takemoto,Tsubasa Sano,Keisuke Kataoka,Satoshi Takahashi,Yukio Nakamura,David G. Kent,Atsushi Iwama,Shigeru Chiba,Shinichiro Okamoto,Hiromitsu Nakauchi,Satoshi Yamazaki
出处
期刊:Nature
[Springer Nature]
日期:2023-02-22
卷期号:615 (7950): 127-133
被引量:63
标识
DOI:10.1038/s41586-023-05739-9
摘要
Haematopoietic stem cells (HSCs) are a rare cell type that reconstitute the entire blood and immune systems after transplantation and can be used as a curative cell therapy for a variety of haematological diseases1,2. However, the low number of HSCs in the body makes both biological analyses and clinical application difficult, and the limited extent to which human HSCs can be expanded ex vivo remains a substantial barrier to the wider and safer therapeutic use of HSC transplantation3. Although various reagents have been tested in attempts to stimulate the expansion of human HSCs, cytokines have long been thought to be essential for supporting HSCs ex vivo4. Here we report the establishment of a culture system that allows the long-term ex vivo expansion of human HSCs, achieved through the complete replacement of exogenous cytokines and albumin with chemical agonists and a caprolactam-based polymer. A phosphoinositide 3-kinase activator, in combination with a thrombopoietin-receptor agonist and the pyrimidoindole derivative UM171, were sufficient to stimulate the expansion of umbilical cord blood HSCs that are capable of serial engraftment in xenotransplantation assays. Ex vivo HSC expansion was further supported by split-clone transplantation assays and single-cell RNA-sequencing analysis. Our chemically defined expansion culture system will help to advance clinical HSC therapies. A culture system allows the long-term expansion of human haematopoietic stem cells (HSCs) in vivo without the use of recombinant cytokines or albumin, with potential applications for clinical therapies involving HSCs.
科研通智能强力驱动
Strongly Powered by AbleSci AI